Transforming growth factor-β2 antibody attenuates fibrosis in the experimental diabetic rat kidney

C Hill1, A Flyvbjerg, R Rasch, M Bak and A Logan1

1Institute of Clinical Research, University of Aarhus, Aarhus, DK-8000, Denmark
2Department of Medicine, University of Birmingham, Edgbaston, Birmingham B15 2TH, UK

Abstract

Diabetic nephropathy is characterised by an increase in glomerular and tubular fibrosis that compromises kidney function. The transforming growth factor-βs (TGF-βs) have been shown to play a major role in fibrosis and we have shown that TGF-β2, in particular, increases coordinately with fibrogenesis in the diabetic kidney. The aim of this study was to investigate the changes in expression of extracellular matrix molecules in the diabetic kidney. The fibrogenic transforming growth factor-β (TGF-β) system (Rocco et al. 1994, Hill et al. 1994, Shankland & Scholey 1994, Sharma & Ziyadeh 1994, Hill et al. 2000) has, in addition to several other growth factor systems (Flyvbjerg 1997, Flyvbjerg et al. 1999), been suggested to play a role in the development of diabetic nephropathy. Diabetic nephropathy accounts for approximately 30% of all new cases of end stage renal failure, making it one of the major causes of end stage renal failure in the Western world (Deckert et al. 1978, Vibert et al. 1982, Mogensen & Christensen 1984, Borch-Johnsen & Kreiner 1987). Early changes in incipient diabetic kidney disease include an increase in kidney size, glomerular volume and kidney function and accumulation of glomerular extracellular matrix, increased urinary albumin excretion (UAE), glomerular sclerosis and tubular fibrosis (Osterby et al. 1967, Seyer-Hansen 1976, Flyvbjerg et al. 1992, Park et al. 1997) Previous studies have shown the importance of the TGF-β axis and suggested its link with fibrosis in the early stages of diabetic nephropathy (Rocco et al. 1992, Shankland & Scholey 1994, Hill et al. 2000).

Studies have shown that a pan-neutralising anti-TGF-β antibody administered in vivo to mice with streptozotocin (STZ)-induced diabetes for 9 days attenuated elevated renal TGF-β1 and TGF-β receptor II mRNA levels and reduced both the diabetes-associated renal/glomerular growth and enhanced renal expression of collagen-IV and fibronectin (Sharma et al. 1996). Previous studies by a different group have used a pan-neutralising TGF-β

In the placebo-treated diabetic rats, blood glucose, food consumption, urinary albumin excretion (UAE) and kidney weights were all significantly higher than in the non-diabetic group (P<0·05, n=24, by ANOVA). In the anti-TGF-β2-treated diabetic rats, kidney weights and UAE levels were decreased when compared with those in placebo-treated diabetics. Western blotting for the procollagen-I C-propeptide in kidney cortices showed a significant increase in levels in placebo-treated diabetic rats compared with non-diabetic controls over the 14 day diabetic period, indicating initiation of fibrogenesis. By contrast, in anti-TGF-β2-treated diabetic rats, levels of the propeptide remained at non-diabetic levels.

In summary, a significant suppression of kidney fibrosis was seen in anti-TGF-β2-treated diabetic rats, compared with placebo-treated diabetic rats. We conclude that systemic delivery of CAT-152, a neutralising anti-TGF-β2 antibody, during the acute stages of diabetic nephropathy reduces the rate of pathogenic fibrosis in the kidney.

Journal of Endocrinology (2001) 170, 647–651

Introduction

The fibrogenic transforming growth factor-β (TGF-β) system (Rocco et al. 1992, Ziyadeh et al. 1992, Pankewycz et al. 1994, Shankland & Scholey 1994, Sharma & Ziyadeh 1994, Hill et al. 2000) has, in addition to several other growth factor systems (Flyvbjerg 1997, Flyvbjerg et al. 1999), been suggested to play a role in the development of diabetic nephropathy. Diabetic nephropathy accounts for approximately 30% of all new cases of end stage renal failure, making it one of the major causes of end stage renal failure in the Western world (Deckert et al. 1978, Vibert et al. 1982, Mogensen & Christensen 1984, Borch-Johnsen & Kreiner 1987). Early changes in incipient diabetic kidney disease include an increase in kidney size, glomerular volume and kidney function and accumulation of glomerular extracellular matrix, increased urinary albumin excretion (UAE), glomerular sclerosis and tubular fibrosis (Osterby et al. 1967, Seyer-Hansen 1976, Flyvbjerg et al. 1992, Park et al. 1997) Previous studies have shown the importance of the TGF-β axis and suggested its link with fibrosis in the early stages of diabetic nephropathy (Rocco et al. 1992, Shankland & Scholey 1994, Hill et al. 2000).

Studies have shown that a pan-neutralising anti-TGF-β antibody administered in vivo to mice with streptozotocin (STZ)-induced diabetes for 9 days attenuated elevated renal TGF-β1 and TGF-β receptor II mRNA levels and reduced both the diabetes-associated renal/glomerular growth and enhanced renal expression of collagen-IV and fibronectin (Sharma et al. 1996). Previous studies by a different group have used a pan-neutralising TGF-β
monoclonal antibody on db/db diabetic mice which prevented a decrease in kidney function seen in type II diabetes (Ziyadeh et al. 2000). Also, Border et al. (1990) administered an anti-TGF-β1 antibody at the time of induction of the glomerular disease, glomerulonephritis, which suppressed the increased production of extracellular matrix and dramatically attenuated histological manifestations of the disease. The impressive suppression of the experimental disease achieved with the anti-TGF-β treatment demonstrates the importance of TGF-β in regulating extracellular matrix production in glomerulonephritis.

Previous work by our group (Hill et al. 2000) has demonstrated that levels of the TGF-β2 isoform rose rapidly in glomeruli and tubules during the acute phase of experimental diabetes (day 3–14) when the rate of synthesis of collagen-I, an extracellular matrix protein, increased maximally in rat kidney cortex. The relative contribution of the TGF-β2 isoform to fibrogenesis in the diabetic kidney is unknown. The study described here shows that systemic delivery of a specific TGF-β2 neutralising antibody, CAT-152, in vivo during the acute pre-fibrotic stages of diabetic nephropathy significantly attenuates the rate of collagen-I synthesis and reduces UAE levels in diabetic rat kidneys. This indicates the fibrogenic activity of the TGF-β2 isoform in the diabetic kidney and the potential for related antagonists in renoprotection in this disease.

Materials and Methods

Antibodies

The antagonist used to block TGF-β2 activity was a recombinant human monoclonal antibody, which was a gift from Cambridge Antibody Technology Ltd, Melbourne, Melbourn, Camb, UK. The antibody, termed CAT-152, was a recombinant IgG4 antibody with a fully human sequence, directed against TGF-β2. The VH and VL variable regions of CAT-152 were obtained by selection on active human TGF-β2 from phage display libraries of human single chain Fv antibody molecules (Jackson et al. 1998). A whole antibody molecule of the IgG4 isotype was then constructed by recombinant techniques and expressed in NS0 myeloma cells and purified. The recombinant antibody, originally termed 6B1, but now named CAT-152, has been well characterised (Thompson et al. 1999). For example, it (i) has a high affinity for TGF-β2 with a dissociation constant of 0.89 nM, as determined by binding to TGF-β2 using the BIACore biosensor (BIACore International AB, Uppsala, Sweden); (ii) shows approximately 9% cross-reactivity with TGF-β3 (dissociation constant 10 nM) compared with TGF-β2; (iii) has no detected binding to TGF-β1; (iv) is specific for the active form of TGF-β2 and does not significantly bind the latent form; (v) strongly neutralises the anti-proliferative effect of TGF-β2 in bioassays using TF1 human erythroleukaemia cells with an IC₅₀ of 1–2 nM; (vi) has strong inhibition of binding of TGF-β2 to cell surface receptors in a radioreceptor assay using A549 cells; (vii) has some ability to neutralise and inhibit TGF-β3 binding, as would be expected from the 9% cross-reactivity; (viii) has no significant ability to inhibit or neutralise TGF-β1 binding as would be expected from the non-detected binding by BIACore; (ix) shows no detected cross-reactivity with related or unrelated antigens by immunocytochemistry and ELISA; and (x) binds to active TGF-β2 from human, rat, mouse, pig and rabbit. Hence, it was appropriate for use as a high-affinity, isoform-specific neutralising antibody for rat TGF-β2 in the rat model employed in this study. An irrelevant IgG4 was used as the control immunoglobulin in the placebo-treated group.

The antibody against procollagen-I C-propeptide was a gift from AstraZeneca plc (Macclesfield, Cheshire, UK) and was used for Western blotting at a dilution of 1:10 000.

Animals

Thirty female Wistar rats (Mollegaards Avlslab, Eiby, Denmark) aged 65 days, weighing approximately 180 g were used in this protocol. All animals had an i.v. catheter surgically inserted into the jugular vein. Once recovered from the operation (3–4 days), 24 rats received 50 mg/kg body weight of STZ via the i.v. catheter on day 0 of the experiment, the other six acted as untreated non-diabetic controls. Twelve diabetic rats were given 5 mg/kg body weight of the anti-TGF-β2 antibody CAT-152 every second day. Twelve diabetic rats and six non-diabetic rats were given 5 mg/kg placebo (an irrelevant IgG4 control immunoglobulin) every second day and acted as placebo-treated controls. Body weight, blood glucose, food consumption and UAE were recorded daily throughout the experimental period. The experiment was terminated at day 14 when the kidneys were removed, weighed and dissected to separate the cortices. The left kidney cortices were snap-frozen for later Western blotting and the right cortices were processed for measurement of glomerular volume as described below. For this part of the study, animal procedures and care were consistent with the licences held by Aarhus University, Denmark, which fulfil and follow international rules and guidelines.

UAE

The urinary albumin concentration in 24 h urine collections was determined by RIA as previously described (Flyvbjerg et al. 1992) using rat albumin antibody and standards. The urine samples were stored at −20 °C until the assay was performed. Rabbit anti-rat albumin antibody RARα/Alb was purchased from Nordic Pharmaceuticals and Diagnostics (Tilburg, Netherlands). For standard and iodination a globulin-free rat albumin was obtained from Sigma Chemical Co. (St Louis, MO, USA).
Table 1 Changes (± S.E.M.) of blood glucose, body weight, food consumption, kidney weight, UAE and glomerular volume measurements in the three groups of rats after 14 days

<table>
<thead>
<tr>
<th></th>
<th>Control non-diabetic rats</th>
<th>Placebo-treated diabetic rats</th>
<th>Anti-TGF-β2 IgG4-treated diabetic rats</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood glucose (mM)</td>
<td>5.7 ± 0.4</td>
<td>27.6 ± 1.2*</td>
<td>24.3 ± 1.5†</td>
</tr>
<tr>
<td>Body weight (g)</td>
<td>221.7 ± 5.2</td>
<td>217.2 ± 4.3</td>
<td>206.3 ± 4.1</td>
</tr>
<tr>
<td>Food consumption (g/24 h)</td>
<td>18 ± 2</td>
<td>34 ± 3*</td>
<td>33 ± 3†</td>
</tr>
<tr>
<td>Kidney weight (mg)</td>
<td>705 ± 5.2</td>
<td>897 ± 4.3*</td>
<td>850 ± 7.6†</td>
</tr>
<tr>
<td>UAE (µg/24 h)</td>
<td>54.0 ± 27.5</td>
<td>153 ± 20.8*</td>
<td>124 ± 16.4†</td>
</tr>
<tr>
<td>Glomerular volume (10^5 µm^3)</td>
<td>4.77 ± 0.68</td>
<td>5.64 ± 0.76</td>
<td>5.67 ± 0.82</td>
</tr>
</tbody>
</table>

*P<0.05, non-diabetic rats compared with placebo-treated diabetic rats; †P<0.05, non-diabetic rats compared with anti-TGF-β2 IgG4-treated diabetic rats.

Western blotting

Western blots were performed on kidney cortex from at least three animals from each group and repeated three times. One hundred micrograms of protein extracted from kidney cortex, and measured by the Bradford procedure detailed elsewhere (Hill et al. 2000), were loaded in each lane of the gel. A 12% polyacrylamide gel was run and blotted onto polyvinylidene difluoride membrane (Bio-Rad, Hemel Hempstead, UK). The membrane was then incubated overnight with the primary antibody and further incubated with a horseradish peroxidase-labelled secondary antibody and then detected using enhanced chemiluminescence (ECL; Amersham International, Amersham, Bucks, UK). The detailed method for protein extraction, protein quantification and Western blotting was previously described (Hill et al. 2000).

Glomerular volume measurements

A 2 mm thick horizontally cut slice from the middle of the right kidney (containing papilla) was fixed in a 4% paraformaldehyde and embedded in Technovit (Heraeus Kulzer, Wehrheim, Germany). Two-micron thick sections were cut on a rotation microtome and stained with phosphotungsten acid and haematoxylin. The mean glomerular tuft volume (V_G) was determined from the mean glomerular cross-sectional area (A_G) by light microscopy as previously described (Weibel 1979, Pagtalunan et al. 1995). Profile areas were traced using a computer-assisted morphometric unit (Image Tool; University of Texas Health Science Centre, San Antonio, TX, USA). A_G was determined as the average area of a total of 40–80 glomeruli (tuft omitting the proximal tubular tissue within the Bowman’s capsule) and V_G calculated as:

V_G=β/k × (A_G)^3/2, where β=1.38 is the shape coefficient for spheres (the idealised shape of glomeruli) and k+1 is a size distribution coefficient (Weibel 1979, Pagtalunan et al. 1995)

Densitometric and statistical analysis

Autoradiographs were scanned into a Macintosh computer and subjected to densitometric analysis using Deskcan II software (Hewlett-Packard, Bracknell, Berks, UK). Densitometric analysis of collagen-I C-propeptide bands in each sample in the Western blots was carried out using NIH image 1·55f software (NIH Shareware; National Institutes of Health, Bethesda, MA, USA). One-way ANOVA was performed on the densitometry results obtained to find which increases were statistically significant when compared with controls.

Results

Metabolic parameters and body weight

Over the 14 day experiment the placebo/antagonist-treated diabetic rats remained hyperglycaemic with blood glucose levels around 25 mM (Table 1). The body weight measurements showed both diabetic groups had growth retardation and hyperphagia when compared with non-diabetic rats (Table 1).

Changes in kidney weight, glomerular volume measurements and UAE

The TGF-β2 antibody, CAT-152, suppressed the increase in both kidney weight and 24 h UAE seen after 14 days in diabetic animals, although not to control levels (Table 1). The small changes in glomerular volume between control and diabetic rats did not reach statistical significance (Table 1).

Changes in procollagen-I C-propeptide

Western blotting was performed on protein homogenised from rat kidney cortex (Fig. 1A). Immunoreactivity of procollagen-I C-propeptide increased approximately 3-fold from non-diabetic control levels to diabetic day 14 (P<0.05, when diabetic rats were compared with non-diabetic control rats). This increase was attenuated by treatment of diabetics for 14 days with TGF-β2 (Fig. 1B), so that at 14 days the levels were not significantly different from those in non-diabetic controls.
Discussion

Overproduction of elements of the TGF-β axis is suggested to be key to fibrosis induction within the diabetic kidney and in other fibrotic disease models. Many investigators have attempted to inactive all or parts of the TGF-β axis to prevent fibrosis. For example, Border et al. (1990, 1992) blocked the TGF-β1 isoform with some success to suppress extracellular matrix production in glomerulonephritis. Others have used a pan-specific anti-TGF-β antibody to block the activity of all three isoforms and have succeeded in reducing extracellular matrix production in the diabetic kidney (Sharma et al. 1996). Still others have used decorin, a naturally occurring antagonist of all TGF-β isoforms, to limit fibrosis in glomerulopathy (Isaka et al. 1996, 1997).

Previously, we have shown by immunocytochemistry and Western blotting that TGF-β2 was the predominantly responsive TGF-β isoform in the glomeruli of the kidney cortex in STZ-induced diabetic rats between days 3 and 14 of diabetes (Hill et al. 2000). Therefore, we speculated that application of a neutralising antibody specific for the TGF-β2 isoform may reduce the amount of fibrosis occurring within the diabetic kidney, and thereby improve early signs of decreasing kidney function.

Like others (El Nehas 1995, Park et al. 1997), we have characterised fibrosis in the kidney by Western blotting for the procollagen-I C-propeptide. The collagen propeptides are necessary for correct folding of the collagen protein. N- and C-terminal propeptides are removed by amino and carboxyl procollagen peptidases, and this occurs prior to collagen-I being laid down in the extracellular matrix. Hence, the presence of C-propeptide is a marker for the rate at which collagen-I is being laid down in the matrix and is, therefore, an adequate indication of when the diabetic kidney initiates fibrosis and when initiation of glomerular scarring is taking place. An antibody against procollagen-I C-propeptide allowed us to examine by Western blotting the rate of collagen-I accumulation during disease induction in the STZ diabetic rat. Clearly, measuring the C-propeptide does not quantify the total amount of collagen-I in the kidney, only the periods of most turnover of procollagen-I to mature collagen-I, i.e., periods of active fibrogenesis. Previous work by us showed that procollagen-I C-propeptide immunoreactivity increased in the kidney cortex from control levels to a peak at day 14 of experimental diabetes and, thereafter, it decreased back to control levels (Hill et al. 2000). This indicated that the period of most active fibrogenesis in the diabetic kidney occurs in the first 14 days of diabetes. Importantly, in the experiment described herein, the levels of procollagen-I C-propeptide were significantly suppressed in the kidney cortices of TGF-β2 antibody-treated diabetic rats when compared with levels in the placebo-treated diabetic rats. The effect was marked so that, by 14 days of experimental diabetes, the levels were not significantly different from those in non-diabetic controls. This observation indicates that systemic delivery of the TGF-β2 antagonist, CAT-152, during the acute stages of diabetic nephropathy was effective in reducing the rate of kidney fibrogenesis.

In the experiment described here, kidney weights and UAE were consistently reduced at 14 days when the anti-TGF-β2 antibody-treated diabetic rats were compared with the untreated diabetic rats although, at this time point, not to levels seen in non-diabetic controls. The incomplete protective effect observed with the anti-TGF-β2 antibody treatment is reminiscent of the results of previous work with other TGF-β antibodies which have never totally prevented fibrosis nor fully corrected kidney glomerulosclerosis (Bordet et al. 1992, Isaka et al. 1996, Sharma et al. 1996). Therefore, it might be concluded that TGF-β2, like the other TGF-β isoforms, may not be alone in initiating fibrosis and compromising kidney function, although the results indicate that it does play an important contributory role. It could be that, when the levels of TGF-β2 are reduced, the other isoforms of TGF-β compensate. Furthermore, the renoprotective effects of CAT-152 may become more marked at...
longer time periods of treatment and optimisation of the antagonist delivery strategy may improve its efficacy.

In summary, our data demonstrate that specifically neutralising the activity of the TGF-ß2 isoform with a recombinant human monoclonal antibody, CAT-152, during the first 14 days of diabetes has a renoprotective effect as it attenuated the synthesis of collagen-I, the rise in kidney weight and the production of urinary albumin. The results confirm the importance of TGF-ß as fibrogenic factors in the diabetic kidney and indicate the potential usefulness of TGF-ß antagonists such as CAT-152 as renoprotective agents.

Acknowledgements

This study was supported by grants from the Danish Medical Research Council (No. 9700592), the Danish Diabetes Association, the Danish Kidney Foundation, the Ruth König Petersen Foundation, the Novo Foundation, the Aage Louis-Hansen Memorial Foundation, the Eva and Henry Fraenkels Memorial Foundation, the Nordic Insulin Foundation and the Aarhus University-Novo Nordisk Centre for Research in Growth and Regeneration (No. 9600822) and the Department of Medicine, University of Birmingham, UK. We are grateful to Mrs Karen Mathiassen, Kirsten Nyborg and Ninna Rosenqvist for excellent technical assistance.

References


Received in final form 21 February 2001
Accepted 30 May 2001